3 β-hydroxysteroid dehydrogenase

3α-Hydroxysteroid dehydrogenase (3α-HSD), encoded by the AKR1C4 gene, is responsible for catalyzing the transformation of 3-ketosteroids into 3α-hydroxy compounds. This enzyme significantly contributes to the inactivation of the androgen DHT by converting it into 3α-androstanediol, which exhibits reduced androgen activity. Such conversions are crucial in hirsutism research [1].

Epostane acts as an antiprogestogen and terminates pregnancy by inhibiting 3β-hydroxysteroid dehydrogenase and preventing the biosynthesis of progesterone and pregnenolone. [4]

Trilostane (Win 24540) is a synthetic androstane derivative with adrenocortical suppressive properties, reversibly inhibiting 3 beta-hydroxysteroid dehydrogenase delta [5-4] isomerase in the adrenal cortex.

2-(Acetyloxy)-3-Methylbenzoic Acid is used in qHTS Assay for Inhibitors of hydroxysteroid (17-beta) dehydrogenase 4, HSD17B4 with activity value of 19.95 μM

3-Acetyl-7-Hydroxycoumarin (Compound 2) is a highly selective inhibitor of 17-β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). At a concentration of 6 μM, it achieves 57% inhibition of 17β-HSD1. 3-Acetyl-7-Hydroxycoumarin shows potential for research into hormone-dependent conditions such as breast cancer and endometriosis.

HSD17B13-IN-96 (3) acts as an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), demonstrating an IC 50 value of less than 0.1 μM for estradiol. This compound is utilized in researching nonalcoholic fatty liver disease [1].

Trilostane-d3 is a deuterium-substituted isotope-labeled compound of Trilostane, which is used primarily as a quantitative tracer.Trilostane is a competitive and specific inhibitor of 3-beta-hydroxysteroid dehydrogenase (3β-HSD), with the advantage of oral activity.Trilostane reduces the synthesis of steroid hormones by inhibiting the activity of 3β-HSD, and can be Used in studies of Cushing's syndrome (hypercortisolism), Con's syndrome (hyperaldosteronism), and postmenopausal breast cancer.